# Esperion Therapeutics

Type: Company

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/esperion-therapeutics
Canonical HTML page: https://getbiobrief.com/entity/esperion-therapeutics

## Recent coverage (1 stories)

### Biotech Weekly: ASND Secures FDA Nod as AARD and TBPH Face Strategic Setbacks
2026-03-06 16:58:03 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Ascendis Pharma achieves a landmark FDA approval for its hypoparathyroidism treatment, while the broader sector sees volatility as Aardvark Therapeutics faces a clinical hold and Theravance Biopharma initiates workforce reductions. Esperion Therapeutics shifts to an aggressive commercial stance following a significant financial resolution.
Full story: https://getbiobrief.com/story/biotech-weekly-asnd-fda-approval-aard-clinical-hold-tbph-layoffs

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.